{"disease":{"id":"genital-herpes","name":"genital herpes"},"drugs":{"marketed":[{"drug_id":"famciclovir","indication_name":"Recurrent genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Famvir","generic_name":"FAMCICLOVIR","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]","quality_score":59,"revenue":null,"mechanism":"Famvir works by inhibiting the replication of herpes simplex virus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"aciclovir","indication_name":"Genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciclovir","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"aciclovir","indication_name":"Recurrent genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciclovir","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"acyclovir","indication_name":"Genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zovirax","generic_name":"ACYCLOVIR","company_name":"Ligand Pharms","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Acyclovir works by mimicking a building block of DNA to prevent the herpes virus from replicating."},{"drug_id":"acyclovir","indication_name":"Recurrent genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zovirax","generic_name":"ACYCLOVIR","company_name":"Ligand Pharms","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Acyclovir works by mimicking a building block of DNA to prevent the herpes virus from replicating."},{"drug_id":"valacyclovir","indication_name":"Genital Herpes (Initial Episode)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."},{"drug_id":"valacyclovir","indication_name":"Genital Herpes (Recurrent Episodes)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."},{"drug_id":"valacyclovir","indication_name":"Suppression of Genital Herpes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."},{"drug_id":"valacyclovir","indication_name":"Reduction of Transmission of Genital Herpes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."},{"drug_id":"valaciclovir","indication_name":"Genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valtrex","generic_name":"valaciclovir","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Valtrex works by inhibiting the replication of herpes simplex virus DNA through interference with viral DNA polymerase."},{"drug_id":"valaciclovir","indication_name":"Recurrent genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valtrex","generic_name":"valaciclovir","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Valtrex works by inhibiting the replication of herpes simplex virus DNA through interference with viral DNA polymerase."},{"drug_id":"acyc","indication_name":"Genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYC","company_name":"Ligand Pharms","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Acyc works by binding to a specific target in the body, although its exact mechanism is unknown."},{"drug_id":"acyc","indication_name":"Recurrent genital herpes simplex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYC","company_name":"Ligand Pharms","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Acyc works by binding to a specific target in the body, although its exact mechanism is unknown."}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05429346","title":"Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity","phase":"","overall_status":"RECRUITING","enrollment_count":339000,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT05675228","title":"Knowledge of Young Adults About Genital Herpes","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Université de Reims Champagne-Ardenne","has_results":false},{"nct_id":"NCT01306084","title":"Viral Infections in Healthy and Immunocompromised Hosts","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06033261","title":"A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":365,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT02910284","title":"Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Genocea Biosciences, Inc.","has_results":false},{"nct_id":"NCT06385327","title":"A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Assembly Biosciences","has_results":false},{"nct_id":"NCT06698575","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Assembly Biosciences","has_results":false},{"nct_id":"NCT03080961","title":"The VIBLOK SAfety and perFormancE Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"CLJI Worldwide","has_results":true},{"nct_id":"NCT03595995","title":"A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"United BioPharma","has_results":false},{"nct_id":"NCT05500053","title":"A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease","phase":"","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Rational Vaccines Inc","has_results":false},{"nct_id":"NCT04714060","title":"UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"UBP Greater China (Shanghai) Co., Ltd","has_results":false},{"nct_id":"NCT03146403","title":"Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Genocea Biosciences, Inc.","has_results":true},{"nct_id":"NCT04222985","title":"Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}